Screener
Halozyme Therapeutics HALO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $23,608 | $20,899 |
| Accrued expenses | 111,861 | 156,193 |
| Current portion of long-term debt, net | 208,970 | — |
| Total current liabilities | 344,439 | 177,092 |
| Long-term debt, net | 1,937,684 | 2,142,630 |
| Other long-term liabilities | 102,681 | 113,863 |
| Deferred tax liabilities, net | 49,061 | 42,924 |
| Total liabilities | 2,433,865 | 2,476,509 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's total current liabilities?
- Halozyme Therapeutics (HALO) reported total current liabilities of $344.44M in Q2 2026.
- How has Halozyme Therapeutics's total current liabilities changed year-over-year?
- Halozyme Therapeutics's total current liabilities increased by 156.5% year-over-year, from $134.28M to $344.44M.
- What is the long-term trend for Halozyme Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's total current liabilities has grown at a -15.9% compound annual growth rate (CAGR), from $421.39M to $177.09M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Halozyme Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude